Multifunctional peptide-PEG intercalating conjugates: Programmatic of gene delivery to the blood-brain barrier

Pharmaceutical Research

Volumn 27, Issue 12, 2010, Pages 2528-2543

  Zhang, Hongwei ^a,c   Gerson, Trevor ^a   Varney, Michelle L ^b   Singh, Rakesh K ^b   Vinogradov, Serguei V ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

ApoE peptide; AZT; Blood brain barrier; Brain capillary endothelial cells; Brain homing peptide; Intercalating complex; MRP4; NLS peptide; Peptide PEG conjugate; Plasmid DNA; TAT peptide

Indexed keywords

ACRIDINE; APOLIPOPROTEIN E; MACROGOL; MULTIDRUG RESISTANCE PROTEIN 4; PLASMID DNA; POLYETHYLENEIMINE; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CELL DIVISION; CELL TRANSPORT; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG UPTAKE; GENE DELIVERY SYSTEM; GENE SILENCING; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN; CELL LINE; DNA; DOWN-REGULATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PEPTIDES; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION; ZIDOVUDINE;

EID: 78651278782     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0256-x     Document Type: Article

References (42)

1. Wagner E. Strategies to improve DNA polyplexes for in vivo gene transfer: Will "artificial viruses" be the answer? Pharm Res. 2004;21:8-14.
2. Bremner KH, Seymour LW, Logan A, Read ML. Factors influencing the ability of nuclear localization sequence peptides to enhance nonviral gene delivery. Bioconjug Chem. 2004;15:152-61.
3. Escriou V, Carriere M, Scherman D, Wils P. NLS bioconjugates for targeting therapeutic genes to the nucleus. Adv Drug Deliv Rev. 2003;55:295-306.
4. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev. 2005;57:579-96.
5. Vendeville A, Rayne F, Bonhoure A, Bettache N, Montcourrier P, Beaumelle B. HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses. Mol Biol Cell. 2004;15:2347-60.
6. Oupicky D, Ogris M, Seymour LW. Development of longcirculating polyelectrolyte complexes for systemic delivery of genes. J Drug Target. 2002;10:93-8.
7. Gilmore JL, Yi X, Quan L, Kabanov AV. Novel nanomaterials for clinical neuroscience. J Neuroimmune Pharmacol. 2008;3:83-94.
8. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6:591-602.
9. Kabanov AV, Batrakova EV. New technologies for drug delivery across the blood brain barrier. Curr Pharm Des. 2004;10:1355-63.
10. Boado RJ. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm Res. 2007;24:1772-87.
11. Zhang H, Mitin A, Vinogradov SV. Efficient transfection of blood-brain barrier endothelial cells by lipoplexes and polyplexes in the presence of nuclear targeting NLS-PEG-acridine conjugates. Bioconjug Chem. 2009;20:120-8.
12. Zhang H, Vinogradov SV. Short biodegradable polyamines for gene delivery and transfection of brain capillary endothelial cells. J Control Release 2010;143:359-66.
13. Chen Z, Varney ML, Backora MW, Cowan K, Solheim JC, Talmadge JE, Singh RK. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res. 2005;65:9004-11.
14. Torchilin VP. Tatp-mediated intracellular delivery of pharmaceutical nanocarriers. Biochem Soc Trans. 2007;35:816-20.
15. Tiera MJ, Winnik FO, Fernandes JC. Synthetic and natural polycations for gene therapy: State of the art and new perspectives. Curr Gene Ther. 2006;6:59-71.
16. Lechardeur D, Lukacs GL. Nucleocytoplasmic transport of plasmid DNA: A perilous journey from the cytoplasm to the nucleus. Hum Gene Ther. 2006;17:882-9.
17. Nguyen J, Xie X, Neu M, Dumitrascu R, Reul R, Sitterberg J, et al. Effects of cell-penetrating peptides and pegylation on transfection efficiency of polyethylenimine in mouse lungs. J Gene Med. 2008;10:1236-46.
18. Deeva EG, Pavlovskaia V, Kiselev OI, Kiselev VI, Piotrovskii LB, Ershov FI. [The structural and functional analysis of the biological activity of acridine derivatives]. Vestn Ross Acad Med Nauk 2004;29-34.
19. Lechardeur D, Verkman AS, Lukacs GL. Intracellular routing of plasmid DNA during non-viral gene transfer. Adv Drug Deliv Rev. 2005;57:755-67.
20. Kloeckner J, Boeckle S, Persson D, Roedl W, OgrisM, Berg K, et al. DNA polyplexes based on degradable oligoethyleniminederivatives: Combination with EGF receptor targeting and endosomal release functions. J Control Release. 2006;116:115-22.
21. Ou M, Wang XL, Xu R, Chang CW, Bull DA, Kim SW. Novel biodegradable poly(disulfide amine)s for gene delivery with high efficiency and low cytotoxicity. Bioconjug Chem. 2008;19:626-33.
22. Bolhassani A, Ghasemi N, Servis C, Taghikhani M, Rafati S. The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen. Drug Deliv. 2009;16:196-204.
23. Moore NM, Clayton CL, Sakiyama-Elbert SE. Characterization of multifunctional PEG-based gene delivery system containing nuclear localization signals and endosome escape peptides. Acta Biomater. 2009;5:854-64.
24. Nitin N, LaConte L, Rhee W-J, Bao G. TAT peptide is capable of importing large nanoparticles across nuclear membrane in digitonin permeabilized cells. Ann Biomed Engin. 2009;37: 2018-27.
25. Sadanandam A, Varney ML, Kinarsky L, Ali H, Mosley RL, Singh RK. Identification of functional cell adhesion molecules with a potential role in metastasis by a combination of in vivo phage display and in silico analysis. OMICS. 2007;11:41-57.
26. Takae S, Miyata K, Oba M, Ishii T, Nishiyama N, Itaka K, et al. PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsive nonviral gene vectors. J Am Chem Soc. 2008;130:6001-9.
27. Kaleand AA, Torchilin VP. Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J Drug Target. 2007;15:538-45.
28. Wan L, Pooyan S, Hu P, Leibowitz MJ, Stein S, Sinko PJ. Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionylleucyl- phenylalanine) nanocarriers for improving HIV drug delivery. Pharm Res. 2007;24:2110-9.
29. Romberg B, Hennink WE, Storm G. Sheddable coatings for longcirculating nanoparticles. Pharm Res. 2008;25:55-71.
30. Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: Expression and function in the central nervous system. Pharmacol Rev. 2006;58:140-61.
31. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem. 2008;15:1981-2039.
32. Labialle S, Dayan G, Michaud M, Barakat S, Rigal D, Baggetto LG. Gene therapy of the typical multidrug resistance phenotype of cancers: A new hope? Semin Oncol. 2005;32:583-90.
33. Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: Evaluation of current strategies. Curr Mol Pharmacol. 2008;1:93-105.
34. Galinsky RE, Hoesterey BL, Anderson BD. Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. Life Sci. 1990;47:781-8.
35. Jorajuria S, Dereuddre-Bosquet N, Becher F, Martin S, Porcheray F, Garrigues A, et al. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther. 2004;9:519-28.
36. Giri N, Shaik N, Pan G, Terasaki T, Mukai C, Kitagaki S, et al. Investigation of the role of breast cancer resistance protein (Bcrp/ Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab Dispos. 2008;36:1476-84.
37. Pan G, Giri N, Elmquist WF. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos. 2007;35:1165-73.
38. Wangand X, Baba M. The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antivir Chem Chemother. 2005;16:213-6.
39. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003;63:1515-9.
40. Gan HZ, Zhang GZ, Zhao JS, Zhang FC, Bu LS, Yang SJ, et al. Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors. Chin Med J (Engl). 2005;118:893-902.
41. Kaszubiak A, Holm PS, Lage H. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti- MDR1 short hairpin RNAs and ribozymes. Int J Oncol. 2007;31:419-30.
42. Su Y, Lee SH, Sinko PJ. Inhibition of efflux transporter ABCG2/ BCRP does not restore mitoxantrone sensitivity in irinotecanselected human leukemia CPT-K5 cells: Evidence for multifactorial multidrug resistance. Eur J Pharm Sci. 2006;29:102-10.